Vanta Bioscience

What does Vanta Bioscience do?

Vanta Bioscience Ltd is a micro-cap company focused on preclinical healthcare services, with recent net sales of 3 Cr and a net profit of -3 Cr as of March 2023. The company has a market cap of Rs 17 Cr and key financial metrics include a P/E ratio of 17.00 and a debt-equity ratio of 1.28.

Overview: <BR>Vanta Bioscience Ltd is engaged in preclinical activities within the healthcare services industry and operates in the micro-cap market segment.<BR><BR>History: <BR>Vanta Bioscience Limited was originally incorporated as a Private Limited Company on 29th April 2016 and converted into a Public Limited Company on 17th March 2017. The latest quarterly results reported net sales and net profit for March 2023.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Cr (Quarterly Results - Mar 2023) <BR>Most recent Net Profit: -3 Cr (Quarterly Results - Mar 2023) <BR>Market-cap value: Rs 17 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 17.00 <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.28 <BR>Return on Equity: 0.25% <BR>Price to Book: 0.84<BR><BR>Contact Details: <BR>Address: No.02/G/308/G Umajay Complex, Rasoolpura Secunderabad Hyderabad Telangana : 500003 <BR>Tel: 91-40-66575454 <BR>Email: info@vantabio.com <BR>Website: http://www.vantabio.com

Has Vanta Bioscience declared dividend?

No Dividend History Available

What is the technical trend for Vanta Bioscience?

As of May 21, 2025, Vanta Bioscience's trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite some bullish signals from the weekly MACD and monthly RSI.

As of 21 May 2025, the technical trend for Vanta Bioscience has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend, while the weekly MACD and KST show a mildly bullish signal. The monthly MACD and KST remain bearish, and the Bollinger Bands also reflect a mildly bearish outlook on both weekly and monthly time frames. The RSI shows no signal on the weekly but is bullish on the monthly, suggesting some potential for upward movement, although the overall sentiment leans towards bearish.

Who are the peers of the Vanta Bioscience?

Vanta Bioscience's peers include Chennai Meena, Samsrita Labs, Adeshwar Meditex, Family Care, Gian Lifecare, Dr Lalchand. Lab, Looks Health, Dhanvantri Jeev., and Clinitech Lab. Key metrics show varying management risks and growth ratings, with Samsrita Labs having the highest 1-year return at 4.43% and Adeshwar Meditex the lowest at -30.77%, while Vanta Bioscience's return is -48.64%.

Peers: The peers of Vanta Bioscience are Chennai Meena, Samsrita Labs, Adeshwar Meditex, Family Care, Gian Lifecare, Dr Lalchand. Lab, Looks Health, Dhanvantri Jeev., and Clinitech Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Clinitech Lab and Sunrest Lifescie, while Average management risk is found at Family Care and Dr Lalchand. Lab. Below Average management risk is noted at Adeshwar Meditex, Gian Lifecare, and Dhanvantri Jeev., and the rest do not qualify. Growth is rated as Good at Family Care and Average at Gian Lifecare, while Below Average growth is seen at Adeshwar Meditex, Dr Lalchand. Lab, and Dhanvantri Jeev., with the rest not qualifying. Capital Structure is Excellent at Family Care, Good at Gian Lifecare and Dr Lalchand. Lab, while Below Average is noted at Adeshwar Meditex and Dhanvantri Jeev., and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Samsrita Labs at 4.43%, while the lowest is Adeshwar Meditex at -30.77%. Vanta Bioscience's 1-year return is -48.64%, which is significantly lower than both. Additionally, several peers, including Chennai Meena, Samsrita Labs, Adeshwar Meditex, Family Care, Gian Lifecare, and Clinitech Lab, have negative six-month returns.

Who are in the management team of Vanta Bioscience?

As of March 2020, the management team of Vanta Bioscience includes Mohan Krishna Mulakala (Chairman), Dopesh Raja Mulakala (Managing Director), Vyasmurti Madhavrao Shingatgeri (Whole-time Director), Padmanabhuni Venkata Appaji (Independent Director), Zoheb Sayani (Company Secretary), Sadhanala Venkata Rao (Whole Time Director & CEO), and Yogeswara Rao Danda (Additional Independent Director). Each member contributes to the company's governance and operations.

As of March 2020, the management team of Vanta Bioscience includes the following individuals:<BR><BR>1. Mohan Krishna Mulakala - Chairman<BR>2. Dopesh Raja Mulakala - Managing Director<BR>3. Vyasmurti Madhavrao Shingatgeri - Whole-time Director<BR>4. Padmanabhuni Venkata Appaji - Independent Director<BR>5. Zoheb Sayani - Company Secretary<BR>6. Sadhanala Venkata Rao - Whole Time Director & CEO<BR>7. Yogeswara Rao Danda - Additional Independent Director<BR><BR>Each member plays a significant role in the governance and operational management of the company.

Who are the top shareholders of the Vanta Bioscience?

The top shareholder of Vanta Bioscience is Mohan Krishna Mulakala, holding 55.22% of the shares. Individual investors own 26.35%, while the highest public shareholder is A Vimalchand with 1.09%.

The top shareholders of Vanta Bioscience include the promoters, with Mohan Krishna Mulakala holding the largest share at 55.22%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is A Vimalchand, who holds 1.09%. Additionally, individual investors collectively own 26.35% of the company's shares.

How big is Vanta Bioscience?

As of 24th July, Vanta Bioscience Ltd has a market capitalization of 20.00 Cr and reported net sales of 3.45 Cr with a net profit loss of 3.92 Cr for the latest quarter ending March 2023. Shareholder's funds are 15.20 Cr, and total assets amount to 85.40 Cr as of March 2024.

As of 24th July, <BR><BR>Market Cap: Vanta Bioscience Ltd has a market capitalization of 20.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest quarter ending March 2023, Vanta Bioscience reported Net Sales of 3.45 Cr and a Net Profit loss of 3.92 Cr.<BR><BR>Balance Sheet Snapshot: The latest annual period reported is March 2024, with Shareholder's Funds amounting to 15.20 Cr and Total Assets of 85.40 Cr.

When is the next results date for Vanta Bioscience?

Vanta Bioscience will announce its results on August 1, 2025.

Vanta Bioscience will declare its results on August 1, 2025.

Is Vanta Bioscience overvalued or undervalued?

As of August 4, 2025, Vanta Bioscience is considered overvalued and risky due to poor financial ratios, including a PE Ratio of -3.38 and an ROE of -31.38%, alongside a year-to-date stock decline of 42.53%, significantly underperforming its peers and the market.

As of 4 August 2025, Vanta Bioscience's valuation grade has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued, given its troubling financial ratios, including a PE Ratio of -3.38, an EV to EBIT of -8.02, and an ROE of -31.38%. These figures suggest that Vanta is struggling to generate profits and is facing substantial operational challenges.<BR><BR>In comparison to its peers, Vanta's ratios starkly contrast with those of Altius Telecom, which boasts a PE Ratio of 55.44, and Embassy Off.REIT at 23.07. This highlights Vanta's underperformance within the healthcare services sector. The company's recent stock performance has also been dismal, with a year-to-date decline of 42.53%, significantly underperforming the Sensex, which has gained 3.69% in the same period. Overall, Vanta Bioscience's financial metrics and peer comparisons strongly indicate that it is overvalued in the current market environment.

How has been the historical performance of Vanta Bioscience?

Vanta Bioscience has experienced significant declines in net sales and profitability, with net sales dropping to 1.96 Cr in March 2025 from 9.72 Cr in March 2024, resulting in an operating loss of -4.15 Cr and negative cash flow from operations. The company's financial position is challenging, marked by increasing liabilities and deteriorating earnings per share.

Answer:<BR>The historical performance of Vanta Bioscience has shown significant fluctuations over the years, particularly in net sales and profitability. In March 2025, net sales dropped to 1.96 Cr from 9.72 Cr in March 2024, which was a decrease from 6.28 Cr in March 2023 and 9.69 Cr in March 2022. The total operating income followed a similar trend, declining from 9.72 Cr in March 2024 to 1.96 Cr in March 2025. The company has faced increasing total expenditure, which reached 6.22 Cr in March 2025, compared to 8.41 Cr in March 2024. This led to an operating profit (PBDIT) of -4.15 Cr in March 2025, a stark contrast to the positive 1.42 Cr in March 2024. Profit before tax also worsened, recording -4.11 Cr in March 2025, down from -2.54 Cr in March 2024. Consequently, the profit after tax for March 2025 was -4.77 Cr, worsening from -2.32 Cr in March 2024. The company's earnings per share (EPS) reflected this decline, falling to -7.56 in March 2025 from -3.68 in March 2024. On the balance sheet, total liabilities increased to 85.88 Cr in March 2025, up from 85.40 Cr in March 2024, while total assets also rose to 85.88 Cr. The cash flow from operating activities turned negative at -2.00 Cr in March 2025, compared to a positive 2.00 Cr in March 2024.<BR><BR>Breakdown:<BR>Vanta Bioscience's financial performance has been characterized by a significant decline in net sales, which fell to 1.96 Cr in March 2025 from 9.72 Cr in the previous year. This decline in revenue has been accompanied by a sharp increase in total expenditure, resulting in an operating loss of -4.15 Cr in March 2025. The company's profitability metrics, including profit before tax and profit after tax, have also deteriorated, with figures of -4.11 Cr and -4.77 Cr respectively for March 2025. The earnings per share have similarly dropped to -7.56. On the balance sheet, total liabilities increased slightly to 85.88 Cr, while total assets matched this figure, indicating a challenging financial position. The cash flow from operating activities has turned negative, reflecting ongoing operational difficulties. Overall, Vanta Bioscience's financial trajectory suggests significant challenges in maintaining revenue and profitability over the recent years.

Why is Vanta Bioscience Ltd falling/rising?

As of 15-Apr, Vanta Bioscience Ltd's stock price is currently stable at Rs 18.22, showing no change from the previous trading session. Despite a recent 19.87% increase over the past week, the stock has a year-to-date decline of 22.47% and a three-year drop of 66.65%, raising concerns about investor confidence and participation.

As of 15-Apr, Vanta Bioscience Ltd's stock price is currently stable at Rs 18.22, showing no change from the previous trading session. However, the stock has demonstrated significant volatility recently, with a notable increase of 19.87% over the past week, outperforming the Sensex, which only rose by 0.71% during the same period. <BR><BR>Today, the stock opened with a substantial gain of 19.41%, reaching an intraday high of Rs 18.22. This performance indicates a strong positive movement in the short term. Despite this, the stock has faced challenges, including a year-to-date decline of 22.47%, which is significantly worse than the Sensex's decline of 8.34%. Over the past three years, Vanta Bioscience Ltd has seen a drastic drop of 66.65%, contrasting sharply with the Sensex's rise of 29.26%.<BR><BR>Additionally, there are concerns regarding investor participation, as the delivery volume has decreased by 76.19% compared to the five-day average, indicating a potential lack of confidence among investors. The stock's moving averages show that while it is currently above the 5-day and 20-day averages, it remains below the longer-term 50-day, 100-day, and 200-day averages, suggesting a mixed outlook.<BR><BR>In summary, while Vanta Bioscience Ltd has experienced a recent rise in stock price, the overall trend remains concerning due to significant declines over longer periods and decreasing investor participation.

Which are the latest news on Vanta Bioscience?